Ernexa Therapeutics Inc. (ERNA) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low24.7·High49.9
P/FCF
N/A
—
5yr avg: N/A
30Y Low57.5·High57.5
P/B Ratio
↓
0.82
↓-98% vs avg
5yr avg: 51.88
30Y Low3.2·High106.2
ROE
↑
-687.5%
↓+17% vs avg
5yr avg: -824.7%
30Y Low-302%·High187%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low1.2·High14.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ERNA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Ernexa Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $8M | $125M | $143M | $147M | $2.7B | $2.3B | $95M | $79M | $154M | $243M |
| Enterprise Value | $1M | $6M | $124M | $178M | $140M | $2.7B | $2.3B | $98M | $80M | $156M | $245M |
| P/E Ratio → | -0.14 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 215.18 | 2109.97 | — | — | — | 4.79 | 3.37 | 7.25 | 10.87 |
| P/B Ratio | 0.82 | 3.15 | 73.62 | 64.25 | 12.17 | 106.20 | 304.08 | 18.64 | 11.37 | 27.86 | 59.64 |
| P/FCF | — | — | — | — | — | — | — | 57.50 | — | — | — |
| P/OCF | — | — | — | — | — | — | — | 34.58 | 57.60 | 280.90 | 10549.24 |
P/E links to full P/E history page with 30-year chart
ERNA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 213.39 | 2613.91 | — | — | — | 4.93 | 3.42 | 7.34 | 11.00 |
| EV / EBITDA | — | — | — | — | — | — | — | 49.95 | 24.74 | 170.76 | 403.07 |
| EV / EBIT | — | — | — | — | — | — | — | — | 1209.89 | — | — |
| EV / FCF | — | — | — | — | — | — | — | 59.21 | — | — | — |
ERNA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have expanded from -31080.9% to -2693.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -687.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 83.5% | -247.1% | — | — | — | 60.4% | 64.1% | 66.7% | 63.6% |
| Operating Margin | — | — | -2693.1% | -31080.9% | — | — | — | -6.1% | 2.0% | -6.6% | -10.2% |
| Net Profit Margin | — | — | -7652.7% | -31864.7% | — | — | — | -10.3% | -1.1% | -5.1% | -13.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -687.5% | -687.5% | -2264.3% | -302.2% | -130.7% | -739.0% | 186.8% | -34.1% | -4.2% | -22.4% | -73.9% |
| ROA | -254.0% | -254.0% | -163.7% | -60.7% | -91.4% | -551.6% | 84.5% | -13.6% | -1.6% | -6.4% | -17.2% |
| ROIC | -840.6% | -840.6% | -63.3% | -76.8% | -310.6% | -845.8% | -64.6% | -11.3% | 4.4% | -14.5% | -22.5% |
| ROCE | -368.9% | -368.9% | -69.8% | -73.9% | -156.4% | -604.5% | -76.4% | -12.1% | 5.6% | -17.2% | -20.5% |
ERNA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $490000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.20 | 0.40 | 18.74 | 0.34 | 0.11 | 0.38 | 1.19 | 0.55 | 0.98 | 2.10 |
| Debt / EBITDA | — | — | — | — | — | — | — | 3.11 | 1.18 | 5.91 | 14.00 |
| Net Debt / Equity | — | -0.58 | -0.61 | 15.35 | -0.60 | -0.56 | 0.17 | 0.55 | 0.18 | 0.37 | 0.70 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 1.44 | 0.38 | 2.22 | 4.66 |
| Debt / FCF | — | — | — | — | — | — | — | 1.71 | — | — | — |
| Interest Coverage | -345.15 | -345.15 | -5.59 | -34.29 | -816.80 | -1654.15 | -616.00 | -7.11 | 0.17 | -1.03 | -4.01 |
Net cash position: cash ($2M) exceeds total debt ($490000)
ERNA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.01x means Ernexa Therapeutics Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.46x to 1.01x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.01 | 1.01 | 0.80 | 1.46 | 1.79 | 5.10 | 0.55 | 1.00 | 1.69 | 0.90 | 1.60 |
| Quick Ratio | 1.01 | 1.01 | 0.80 | 1.46 | 1.79 | 5.10 | 0.55 | 0.82 | 1.06 | 0.44 | 1.15 |
| Cash Ratio | 0.61 | 0.61 | 0.59 | 1.15 | 1.50 | 4.62 | 0.52 | 0.53 | 0.64 | 0.31 | 0.86 |
| Asset Turnover | — | — | 0.11 | 0.00 | — | — | — | 1.30 | 1.57 | 1.28 | 1.30 |
| Inventory Turnover | — | — | — | — | — | — | — | 7.20 | 3.30 | 1.46 | 2.71 |
| Days Sales Outstanding | — | — | 274.06 | 2281.25 | — | — | — | 22.02 | 17.88 | 12.25 | 15.18 |
ERNA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Ernexa Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 1.7% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $252280 | $1M | $212560 | $122040 | $86600 | $69314 | $2875 | $2688 | $2442 | $1903 |
Peer Comparison
Compare ERNA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ERNAYou | $2M | -0.1 | — | — | — | — | -687.5% | -840.6% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 SGMO | $22M | -0.2 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 PRME | $562M | -2.3 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
See ERNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ERNA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ERNA vs FATE
Side-by-side business, growth, and profitability comparison vs Fate Therapeutics, Inc..
Start ComparisonERNA — Frequently Asked Questions
Quick answers to the most common questions about buying ERNA stock.
What is Ernexa Therapeutics Inc.'s P/E ratio?
Ernexa Therapeutics Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Ernexa Therapeutics Inc.'s ROE?
Ernexa Therapeutics Inc.'s return on equity (ROE) is -687.5%. The historical average is -71.1%.
Is ERNA stock overvalued?
Based on historical data, Ernexa Therapeutics Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.